Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 1 1

Status

Terminated 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2

Conditions

Squamous Cell Carcinoma of Head and Neck 3Lymphoma 2Head and Neck Neoplasms 2Fallopian Tube Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma, Ovarian Epithelial 1Brenner Tumor 1

Interventions

pembrolizumab 72Cisplatin 57Cetuximab 38Fluorouracil 25Nivolumab 21Radiotherapy 20Carboplatin 19Paclitaxel 14Docetaxel 11Cyclophosphamide 9Gefitinib 8fludarabine 7durvalumab 7zalutumumab 6atezolizumab 6Drug Therapy 6Bleomycin 6epacadostat 5cemiplimab 5Radiotherapy, Intensity-Modulated 5Pemetrexed 5Ipilimumab 5Gemcitabine 5Afatinib 5spartalizumab 4Standard of Care 4Radiation 4Injections 4Immune Checkpoint Inhibitors 4Fibroblast Growth Factor 7 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Head and Neck Neoplasms × VTX-2337 × Clear all
NCT03906526 2023-02-24

A Study to Evaluate Immune Biomarker Modulation in Response to VTX-2337 in Combination With an Anti- PD-1 Inhibitor in Head and Neck Cancer

Celgene

Phase 1 Terminated
15 enrolled
Head & Neck

Carcinoma, Squamous Cell, Head and Neck Neoplasms

NCT04272333 2022-04-14

Intratumoral Microdosing of Motolimod in HNSCC

Presage Biosciences

Phase EARLY_PHASE1 Terminated
1 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡